Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study.

ABSTRACT: Multiparametric assays for risk stratification are widely used in the management of both node negative and node positive hormone receptor positive invasive breast cancer. Recent data from multiple sources suggests that different tests may provide different risk estimates at the individual patient level. The TEAM pathology study consists of 3284 postmenopausal ER+ve breast cancers treated with endocrine therapy Using genes comprising the following multi-parametric tests OncotypeDx^®, Prosigna™ and MammaPrint^® signatures were trained to recapitulate true assay results. Patients were then classified into risk groups and survival assessed. Whilst likelihood χ² ratios suggested limited value for combining tests, Kaplan-Meier and LogRank tests within risk groups s

SUBMITTER: Bartlett JMS 

PROVIDER: S-EPMC8266887 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature